Visibility of phospholipids in 31P NMR spectra of human breast tumours in vivo
- 1 January 1992
- journal article
- research article
- Published by Wiley in NMR in Biomedicine
- Vol. 5 (1) , 37-42
- https://doi.org/10.1002/nbm.1940050107
Abstract
The aims of this study were two-fold: to characterize the in vivo 31P NMR spectrum of human breast tumours by identifying the metabolites contributing to each peak; and to demonstrate changes in the detectability of the phosphodiester (PDE) peak at varying field strengths. This was achieved by obtaining 31P spectra from 23 patients in vivo at 1.5 T and also of 11 perchloric acid (PCA) extracts and 3 chloroform-methanol (CM) extracts of tumour biopsy samples at 9.4 T. In spectra acquired in vivo the percentage areas for each peak were: phosphomenoester (PME), 15%; Pi, 11%; PDE 35%; phosphocreatine, 5%; γ-NTP, 11%; α-NTP, 11% and β-NTP, 12% of the total spectral area. PCA extracts showed the PME peak to be > 70% phosphorylethanolamine whilst the PDE peak included almost equal proportions of glycerophosphorylethanolamine and glycerophosphorylcholine. CM extracts of tumours revealed additional metabolites in the PDE region suggesting that the large PDE peak observed in vivo could arise mainly from phospholipids. Spectra of human breast tumour xenografts examined in vivo at both 1.9 T and 9.4 T confirmed that the presence of a large PDE peak in vivo was a function of field strength. Further experiments with microsomal membranes from rat mammary tumours at 1.5 and 9.4 T demonstrated that phospholipids are more clearly visible at the lower field strength due to a substantial decrease in linewidth.Keywords
This publication has 23 references indexed in Scilit:
- Monitoring therapeutic response of human superficial tumors using phase‐encoded spectroscopyMagnetic Resonance in Medicine, 1989
- Phosphodiesters in the Liver: The Effect of Field Strength on the 31P SignalMagnetic Resonance in Medicine, 1989
- An automated iterative algorithm for the quantitative analysis of in vivo spectra based on the simplex optimization methodMagnetic Resonance in Medicine, 1989
- Therapeutic response of breast carcinoma monitored by 31P MRS in situMagnetic Resonance in Medicine, 1989
- Noninvasive quantitation of phosphorus metabolites in human tissue by NMR spectroscopyJournal of Magnetic Resonance (1969), 1989
- Rapid31P NMR test of liver functionMagnetic Resonance in Medicine, 1988
- A versatile multinuclear probe designed for in vivo NMR spectroscopy: Applications to subcutaneous human tumors in miceMagnetic Resonance in Medicine, 1988
- STUDY OF HEREDITARY FRUCTOSE INTOLERANCE BY USE OF 31P MAGNETIC RESONANCE SPECTROSCOPYThe Lancet, 1987
- 31P NMR detection of mobile dog brain phospholipidsMagnetic Resonance in Medicine, 1986
- NMR study of in vivo RIF-1 tumorsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1984